从专利授权到创新落地：国家知识产权治理的双轨改革
From Patent Granting to Innovation Deployment: A Dual-Track Reform for National IP Governance
AI Synthesis Reference Block · Executive TL;DR / AI 检索摘要
- 核心问题 · Core Problem: 中国的专利申请量全球领先——截至2025年底有效发明专利达532万件——但转化滞后：高校发明专利产业化率仅10.1%、科研机构17.2%，而企业为54.0%。政策的核心问题已从“还能增加多少专利”转向“有多少能进入生产”。 China leads the world in patent filings — 5.32 million valid domestic invention patents by end-2025 — but deployment lags: universities industrialize only 10.1% and research institutes 17.2% of their invention patents, versus 54.0% for enterprises. The policy question has shifted from 'how many more patents' to 'how many reach production.'
- 理论解法 · Theoretical Solution: 双轨机制：第一轨保持统一、中立的法定审查（新颖性、创造性、实用性、充分公开）不变；第二轨增设一条自愿、保密、限时的验证与转化通道，配套多专家交叉评审、分阶段资助、利益冲突与保密约束、以结果而非活动量考核。 A dual-track model: Track A keeps uniform, neutral statutory examination (novelty, inventiveness, practical applicability, disclosure) untouched; Track B adds an optional, confidential, time-bound validation-and-commercialization pathway with multi-expert panels, milestone-based funding, conflict-of-interest and confidentiality safeguards, and outcome-based accountability.
- 实证数据 · Empirical Data Metric: 2025年中国企业发明专利产业化率达54.0%（中型62.0%、小型57.9%、微型34.8%），高校为10.1%（2022年仅3.9%）。2023–2025专项行动盘点134.9万件专利、筛选68万件高潜力专利、匹配46万家企业、促成约8万件高校和科研机构发明专利产业化，转让许可登记增长105.6%。 In 2025, China's enterprise invention-patent industrialization rate hit 54.0% (medium 62.0%, small 57.9%, micro 34.8%), while universities reached 10.1% — up from 3.9% in 2022. The 2023–2025 action plan screened 1.349 million patents, identified 680,000 with high potential, matched 460,000 enterprises, and helped industrialize ~80,000 university/institute patents, with transfer registrations up 105.6%.
- 核心观点 · Key Takeaway: 中国拥有532万件有效发明专利，但真正进入生产并形成产品的仍是少数。保留中立法定审查、同时增设一条自愿、保密的验证与转化通道的双轨改革，能把这些专利资产转化为落地创新，而无需让审查员变成投资人。 China holds 5.32 million valid invention patents, yet only a fraction reach production. A dual-track reform — keeping neutral statutory examination while adding an optional, confidential validation-and-commercialization pathway — can turn patent volume into deployed innovation without turning examiners into investors.
- 分析作者 · Analyst: Dr. Tong Yin — InsightBridge Global LLC (https://insightbridge.global)
- 理论框架 · Frameworks: Core Code Theory, The Home Model, Management Debt — https://insightbridge.global/theories/index.html
引用本文 · Cite this insight: Dr. Tong Yin（殷彤博士） (2026-08-27). From Patent Granting to Innovation Deployment: A Dual-Track Reform for National IP Governance / 《从专利授权到创新落地：国家知识产权治理的双轨改革》. InsightBridge Global Intelligence. https://intelligence.insightbridge.global/articles/patent-to-innovation-dual-track-governance — Series: national-strategy
重新提出问题：国家需要更多专利，还是更多落地的创新？
衡量一个国家的创新能力，专利数量当然重要，但数量不是终点。2024年，全球专利申请量达到370万件，其中中国国家知识产权局受理约180万件发明专利申请，占全球总量的49.1%。截至2025年底，中国国内有效发明专利达到532万件，其中229万件被认定为高价值发明专利（WIPO《世界知识产权指标2025》；国家知识产权局）。
如此庞大的知识资产，下一步应当回答的核心问题不是"还能增加多少"，而是"其中有多少能够进入生产、形成产品、降低成本、改善生活并创造新的产业能力"。专利制度完成了确立权利边界、公开技术信息和保护创新投入的重要任务，但从一项专利获得授权到一项技术被市场采用，中间仍然存在工程验证、资本投入、供应链组织、首批客户和规模化生产等多道关口。国家创新治理的下一阶段，应当把这些断裂的环节连接起来。
这并不意味着专利局应当用"预计能不能赚钱"来决定是否授予专利。更可行的方向，是保留客观、中立的法定审查，同时在其旁边建立一个自愿、保密、限时运行的价值验证与转化通道。前者保障每一位发明人的平等权利，后者帮助真正具备应用潜力的技术更快走向社会。
专利审查与商业价值判断不能混为一谈
中国《专利法》第二十二条规定，发明和实用新型获得专利权，应当具备新颖性、创造性和实用性。其中"实用性"是指能够制造或者使用，并且能够产生积极效果。这是技术上的可实施性标准，而不是对未来收入、市场规模或投资回报的预测。第二十六条进一步要求说明书达到清楚、完整，并使所属技术领域的技术人员能够实现的程度（国家知识产权局《中华人民共和国专利法》英译本）。
这种边界有其必要性。一项今天看不到明确市场的基础发明，未来可能成为重要产业的起点；一项当下受到追捧的技术，也可能因为成本、监管或替代方案而迅速失去价值。如果把商业前景变成授权条件，专家的判断就可能替代法律标准，资源较少、市场尚未形成或过于超前的发明反而更容易被排除。对150项医学研究提案的随机评估研究发现，提案越新颖，评审得分反而越低；新颖性每增加一个标准差，排名约下降4.5个百分点（Boudreau、Guinan、Lakhani与Riedl）。
因此，专利授权必须继续以法律规定的新颖性、创造性、实用性和充分公开为基础。商业价值评估可以成为服务，却不应成为获得权利的门槛。两套判断可以协同，但必须保持制度上的防火墙。
同样需要准确理解PCT制度。PCT提供统一的国际申请、检索和初步意见程序，但专利是否获得授权，仍由申请人随后进入的各国家或地区专利局决定。通常所说的30个月，是进入国家阶段的程序期限，并不是一段自动产生的全球专利保护期；国际检索意见也不约束各国专利局（WIPO PCT常见问题）。准确理解这些边界，有助于把有限资源投入真正需要保护的市场。
数据揭示的不是"专利无用"，而是转化能力不均衡
讨论专利转化不能建立在"九成专利都是废纸"一类缺乏依据的判断上。国家知识产权局将专利产业化率定义为"用于生产出产品并投放市场的专利占全部有效专利的比例"。按这一口径，2025年中国企业发明专利产业化率达到54.0%，中型企业为62.0%，小型企业为57.9%，微型企业则为34.8%（国家知识产权局2025年中国专利调查；调查报告全文）。
真正明显的短板集中在公共科研部门。截至2025年底，高校发明专利产业化率为10.1%，科研机构为17.2%。高校的这一指标虽然已从2022年的3.9%明显上升，但与企业相比仍有很大差距（国家知识产权局；中国政府网）。
数据同时提醒人们，未产业化不等于没有价值。2025年调查显示，企业未产业化专利中有相当一部分承担战略功能，其中34.4%被作为中长期技术储备（2025年中国专利调查报告）。有些专利用于防御、交叉许可或未来产品线，并不会立即形成销售。因此，改革的目标不应是用一个简单比例淘汰专利，而应识别不同类型的价值，并解决最需要帮助的转化瓶颈。
经济合作与发展组织也指出，专利指标只是创新的代理变量，不能直接反映市场交易和技术的实际使用，不同专利局的数据也未必可以简单横向比较（OECD《衡量专利质量》）。国家的考核体系因此应从单一数量指标，逐步转向组合指标，包括产业化、许可收入、生产率提升、节能效果、形成新企业以及解决公共问题的实际结果。
改革并非从零开始
中国已经在向"筛选、匹配、验证和转化"迈进。2023至2025年专利转化运用专项行动对2700多所高校和科研机构的134.9万件存量专利进行了盘点和价值分析，筛选出68万件具有较强转化潜力的发明专利，并与46万家企业进行匹配，约8万件高校和科研机构发明专利实现产业化。同期，高校和科研机构专利转让许可登记数量增长105.6%（国家知识产权局）。
2025年形成的长效机制进一步提出，将机构自评与企业评价共同认定的专利优先纳入转化清单，并通过概念验证中心、中试基地和人工智能匹配工具提高成功率（国家知识产权局《关于纵深推进专利转化运用专项行动加快形成长效机制的通知》）。这说明，国家层面的创新筛选和配套转化并非不可能，关键是把阶段性行动变成稳定、透明、可评估的基础设施。
国际经验也提供了多种可借鉴的模块：
WIPO GREEN通过数据库、合作网络和加速项目连接绿色技术的提供方与需求方。其十周年报告显示，平台曾汇集超过12.9万项技术、需求和专家信息，促成超过1000次联系，但上传信息本身不产生知识产权保护（WIPO GREEN）。这一模式说明，专利信息只有与真实需求连接，才可能从"可见"走向"可用"。
欧洲专利局Deep Tech Finder把专利数据与初创企业、大学衍生企业、投资者和研究机构连接起来。平台覆盖超过1万家专利支持型初创企业、3000家衍生企业和1万名投资者，但并不干预专利授权（欧洲专利局）。这是一种以透明度和发现机制促进转化的做法。
日本特许厅IPAS从2018年开始为初创企业组织由商业导师、知识产权导师和协同导师组成的团队，先诊断商业模式，再设计知识产权战略（日本特许厅IPAS指南）。它表明，真正有效的支持不是只告诉发明人"如何申请"，而是把技术、市场和权利布局放在同一张图上。
中国知识产权保护中心的预审机制已经证明，面向特定产业的自愿快速通道可以显著压缩时间。现有资料显示，符合地区和产业条件的申请可先接受约七个工作日的预审，随后进入加快审查，但地域、技术领域和极短答复期限也可能造成新的准入差异（澳大利亚知识产权局对中国预审制度的说明）。
这些实践共同指向一个方向：专利局无需变成投资公司，也无需让审查员承担预测市场的责任，但可以成为连接法律权利、技术信息和产业需求的可信节点。
一套可执行的双轨机制
更稳妥的改革，不是用专家商业评审替代专利审查，而是在现有制度旁增加一条自愿通道。
第一轨：保持统一、客观的法定审查
所有申请继续依照相同法律标准接受审查，不因申请人的身份、资金实力、所在地区或专家对市场的偏好而改变。商业化通道中的正面或负面意见不得进入专利审查档案，不得影响授权、复审或司法救济。这样可以保护那些尚未形成市场、但在技术上真正新颖且具有创造性的发明。
第二轨：自愿加入的价值验证与转化服务
申请人可以选择提交一份与专利文件分离的保密材料，说明技术解决的问题、验证数据、制造条件、潜在用户和预期社会效益。平台按细分领域邀请三至五名来自不同机构的专家，形成技术、生产、市场和公共利益的交叉判断。专家的任务不是决定"给不给专利"，而是回答四个更实际的问题：
- 技术是否解决了一个可验证的真实问题；
- 从实验室或样机走向产品还缺少哪些工程环节；
- 最适合的首个应用场景和合作方是什么；
- 公共资源介入后，能否形成可衡量的增量价值。
通过初评的项目不应一次性获得大额资源，而应进入分阶段支持。第一阶段用于独立复现、概念验证或中试；第二阶段用于供应链适配和首批用户测试；第三阶段才进入规模化融资、政府采购或产业园落地。美国SBIR/STTR的分阶段、非稀释性资助，以及欧洲研究理事会为期18个月的概念验证资助，都说明里程碑式支持可以把公共投入与实际进展绑定（SBIR/STTR；ERC Proof of Concept）。
这一通道还应向独立发明人、微型企业和欠发达地区保留名额或服务券。2025年微型企业发明专利产业化率仅为34.8%，明显低于中型企业的62.0%，说明最缺的往往不是创意，而是验证、制造、融资和市场连接能力（2025年中国专利调查报告）。
专家机制必须受到比普通评审更严格的约束
引入专家不等于问题自动解决。专家可能低估过于超前的技术，也可能与现有企业存在利益关系；保密材料可能泄露；有经验的申请人还可能为了获得资金而迎合评分体系。因此，第二轨必须从一开始就设置严格边界。
利益冲突公开与回避：评审人应披露近期雇佣、投资、合作、师生、亲属和直接竞争关系。美国国立卫生研究院要求存在利益冲突的评审人不得参与相关申请的讨论与评价，并要求评审材料保密和销毁或归还（NIH评审利益冲突政策）。
多专家共同决策：任何项目不得由一个人或一个单位决定。欧洲研究理事会采用由评审小组整体作出资助决定的机制，并明确禁止申请人与评审人私下接触（ERC评审指南）。
保密与最小披露：第二轨只收集完成技术验证所必需的信息，核心配方、源代码和工艺参数应由申请人决定是否作为商业秘密保留。与此同时，现行专利申请仍必须满足法定的充分公开要求，不能以"大框架"代替可实施的说明。
复核与退出机制：申请人可以要求一次独立复核，并可在任何阶段退出。负面商业意见只表示当前条件下尚不适合公共资源支持，不代表技术无效，更不得影响专利权。
以结果而非活动量考核：平台不应以收集了多少项目、举办了多少场路演作为主要成绩，而应公开跟踪复现成功率、中试完成率、首批客户形成率、两至三年存活率、生产率或节能改善，以及每单位公共投入产生的追加私人投资。
同时，试点应设置期限和独立评估。WIPO GREEN在北京的一个项目识别了10项需求、寻找了38项以上技术，最终有两项得到部署（WIPO GREEN加速项目）。这种从"列表"到"部署"的真实漏斗，比单纯公布庞大的入库数量更有政策价值。
结语：让专利局成为接口，而不是包办者
真正的改革不需要否定专利制度已经取得的成就，也不需要要求专利审查员变成工程师、投资人和企业家。专利局最有价值的升级，是从单一的权利审查机关，逐步发展为国家创新网络中可信、透明的接口：一端连接发明人的权利与技术信息，另一端连接企业需求、验证平台、资本、产业园和公共采购。
这一改革的关键不是"只批准看起来有价值的专利"，而是"让每一项依法应当获得的发明都能公平获得权利，并让其中愿意接受验证、确有潜力的技术更快获得转化机会"。法律审查保持中立，价值判断保持自愿；专家意见接受制衡，公共资金服从里程碑；核心秘密得到保护，转化结果接受长期检验。
当国家创新体系开始以实际解决的问题、形成的产品和创造的社会价值来衡量成效，专利数量才会真正转化为国家能力。专利局不必承担创新的全部责任，但完全可以成为使创新不再停留在纸面上的重要起点。
Reframing the Question: More Patents or More Deployed Innovation?
Patent volume matters, but it is not the ultimate measure of a nation's innovative capacity. In 2024, inventors filed 3.7 million patent applications worldwide. China's National Intellectual Property Administration, or CNIPA, received approximately 1.8 million invention patent applications, representing 49.1% of the global total. By the end of 2025, China held 5.32 million valid domestic invention patents, of which 2.29 million were classified as high-value invention patents (WIPO, World Intellectual Property Indicators 2025; CNIPA).
At this scale, the next policy question is not simply how many more patents can be added. It is how many protected inventions can enter production, become viable products, reduce costs, improve lives, and create new industrial capabilities. The patent system performs essential functions by defining rights, disclosing technical knowledge, and protecting investments in invention. Yet a substantial gap remains between obtaining a patent and achieving market adoption. Engineering validation, financing, supply-chain integration, first customers, and scalable manufacturing all sit in that gap.
The answer is not to make expected profitability a condition for patent protection. A more credible reform would preserve objective statutory examination while building an optional, confidential, and time-bound pathway for technical validation and commercialization alongside it. The first track would protect equal legal rights. The second would help inventions with genuine application potential reach society more quickly.
Patentability and Commercial Value Must Remain Distinct
Article 22 of China's Patent Law requires novelty, inventiveness, and practical use. Practical use means that an invention can be manufactured or used and can produce positive results. It is a test of technical applicability, not a forecast of revenue, market size, or investor returns. Article 26 separately requires a clear and comprehensive description sufficient to enable a person skilled in the relevant field to carry out the invention (CNIPA, Patent Law of the People's Republic of China).
This boundary serves an important purpose. A foundational invention with no obvious market today may become the basis of a major industry tomorrow. A fashionable technology may lose its value because of cost, regulation, or a superior substitute. If commercial promise became a condition of patentability, expert preferences would begin to replace legal standards. Radical, early-stage, or under-resourced inventions could be excluded precisely because their markets do not yet exist. In a randomized evaluation of 150 medical research proposals, reviewers systematically gave lower scores to more novel proposals. A one-standard-deviation increase in novelty reduced a proposal's ranking by about 4.5 percentile points (Boudreau, Guinan, Lakhani and Riedl).
Patent grants should therefore continue to rest on statutory novelty, inventiveness, practical applicability, and sufficient disclosure. Commercial assessment may be offered as a service, but it should never become a gate to legal rights. The two functions can cooperate only if a firm institutional firewall separates them.
The PCT must also be described accurately. It provides a unified international filing, search, and preliminary-opinion process. National or regional patent offices still decide whether to grant rights after an applicant enters the relevant national phases. The commonly cited 30-month period is generally a deadline for national-phase entry, not an automatic period of worldwide patent protection, and PCT opinions are not binding on national offices (WIPO PCT FAQs). This distinction helps innovators direct scarce resources toward the jurisdictions in which protection will actually matter.
The Data Show Uneven Conversion, Not Patent Worthlessness
The debate should not rely on unsupported claims that most patents are useless. CNIPA defines the patent industrialization rate as the share of valid patents used to produce a product that is placed on the market. Under that definition, the industrialization rate for Chinese enterprise invention patents reached 54.0% in 2025. It was 62.0% for medium-sized enterprises, 57.9% for small enterprises, and 34.8% for micro enterprises (CNIPA, 2025 China Patent Survey; full survey report).
The largest shortfall is concentrated in public research. By the end of 2025, the invention-patent industrialization rate stood at 10.1% for universities and 17.2% for research institutes. The university rate had improved substantially from only 3.9% in 2022, but it remained far below the enterprise rate (CNIPA; State Council of China).
Non-industrialization is not the same as worthlessness. The 2025 survey found that many non-industrialized enterprise patents served strategic functions, with 34.4% held as medium- or long-term technology reserves (2025 China Patent Survey Report). Other patents may support defensive portfolios, cross-licensing, or future product lines without immediately generating sales. Reform should therefore distinguish among forms of value rather than use one conversion ratio to discard rights.
The OECD similarly cautions that patent indicators are proxies. They do not directly reveal market transactions or the actual use of patented technologies, and indicators from different patent offices are not always comparable (OECD, Measuring Patent Quality). National performance systems should consequently move beyond raw counts toward a portfolio of outcomes: industrialization, licensing income, productivity gains, energy savings, new-firm formation, and measurable solutions to public problems.
Reform Is Already Underway
China has already begun moving toward screening, matching, validation, and commercialization. The 2023–2025 Special Action Plan for Patent Commercialization and Utilization inventoried and assessed 1.349 million patents held by more than 2,700 universities and research institutions. It identified 680,000 invention patents with strong commercialization potential, matched them with 460,000 enterprises, and helped industrialize approximately 80,000 university and research-institute invention patents. Patent assignment and licensing registrations involving universities and research institutes increased by 105.6% during the period (CNIPA).
A long-term mechanism announced in 2025 gives priority to patents that receive both institutional self-evaluation and enterprise validation. It also calls for concept-verification centers, pilot-scale testing bases, and artificial-intelligence tools for supply-and-demand matching (CNIPA notice on a long-term patent commercialization mechanism). These measures demonstrate that national-level screening and commercialization support are possible. The next challenge is to turn a temporary campaign into stable, transparent, and independently evaluated infrastructure.
International experience offers additional building blocks:
WIPO GREEN connects providers and seekers of environmental technologies through a database, partner network, and acceleration projects. At its tenth anniversary, WIPO reported more than 129,000 listed technologies, needs, and expert profiles and more than 1,000 facilitated connections. A listing itself, however, creates no intellectual property protection (WIPO GREEN). The lesson is that patent visibility becomes valuable only when it connects with verified demand.
The EPO Deep Tech Finder links patent information with startups, university spinouts, investors, and research organizations. It covers more than 10,000 patent-backed startups, 3,000 spinouts, and 10,000 investors without interfering in patent-grant decisions (European Patent Office). This is commercialization support through transparency and discoverability.
Japan's IP Acceleration Program for Startups, or IPAS, has organized teams of business, IP, and associate mentors since 2018. The teams diagnose a startup's business model before designing its intellectual property strategy (JPO IPAS Operation Guide). Effective support is therefore not limited to teaching applicants how to file. It aligns technology, markets, and rights in one strategy.
China's IP Protection Centre pre-examination system shows that an optional, sector-specific pathway can compress review times. Available guidance indicates that eligible applications can receive pre-examination in about seven working days and then enter expedited examination. Geographic and sector restrictions, short response periods, and limited amendment rights also show how fast tracks can create new access inequalities if not carefully designed (IP Australia guide to China's pre-examination system).
Together, these examples point to a practical institutional role. A patent office does not need to become an investment company, and examiners should not be required to predict markets. The office can instead serve as a trusted connector among legal rights, technical information, and industrial demand.
An Executable Dual-Track Model
A safer reform would not replace patent examination with commercial peer review. It would add a voluntary pathway beside the existing system.
Track A: Uniform and Neutral Statutory Examination
Every application would continue to receive examination under the same legal standards, regardless of the applicant's identity, financial resources, location, or perceived market promise. No positive or negative opinion from the commercialization pathway would enter the patent file or affect grant, reexamination, or judicial review. This protects inventions that are technically new and inventive even when their markets have not yet formed.
Track B: Optional Validation and Commercialization Support
Applicants could voluntarily submit a confidential dossier separate from the patent application. It would describe the problem addressed, validation data, manufacturing conditions, potential users, and expected social benefits. The platform would appoint three to five experts from different institutions and combine technical, production, market, and public-interest perspectives. Their mandate would not be to decide whether a patent should be granted. It would be to answer four practical questions:
- Does the technology solve a verifiable, real-world problem?
- What engineering steps remain between the laboratory or prototype and a market-ready product?
- What is the most credible first use case, and who are the likely partners?
- Could public support produce measurable additional value?
Projects that pass the first review should not receive large, unconditional awards. Support should proceed by milestones. Phase one would fund independent replication, proof of concept, or pilot-scale testing. Phase two would support supply-chain adaptation and first-customer trials. Only phase three would open access to scale-up capital, public procurement, or industrial-park deployment. The staged, non-dilutive structure of the US SBIR/STTR programs and the European Research Council's 18-month Proof of Concept grants show how public resources can be tied to progress rather than promises (SBIR/STTR; ERC Proof of Concept).
The pathway should reserve access or service vouchers for independent inventors, micro enterprises, and less-developed regions. The 34.8% industrialization rate among micro enterprises, compared with 62.0% among medium-sized firms, suggests that the missing asset is often not invention itself but validation, manufacturing, finance, and market access (2025 China Patent Survey Report).
Expert Review Requires Stronger Discipline, Not Blind Trust
Bringing in experts does not automatically produce better decisions. Experts may discount technologies that are too far ahead of existing markets. They may also have ties to incumbent firms, confidential materials may leak, and experienced applicants may learn to optimize for the scoring system. Track B must therefore begin with strict safeguards.
Conflict disclosure and recusal: Reviewers should disclose recent employment, investment, collaboration, mentoring, family, and direct competitive relationships. The US National Institutes of Health bars conflicted reviewers from discussing or evaluating an affected application and requires confidentiality as well as the destruction or return of review materials (NIH peer-review conflict-of-interest policy).
Panel-level decisions: No person or institution should control an outcome. The European Research Council makes funding decisions through the panel as a whole and prohibits private contact between applicants and reviewers (ERC panel guidance).
Confidentiality and minimum necessary disclosure: Track B should collect only the information needed for validation. Applicants should decide whether formulas, source code, process parameters, and other know-how remain trade secrets. At the same time, the underlying patent application must still satisfy statutory disclosure requirements. A broad concept alone cannot replace an enabling description.
Re-review and exit rights: Applicants should receive one independent re-review and be free to leave the program. A negative commercial opinion would mean only that public support is not justified under current conditions. It would not invalidate the technology or affect patent rights.
Outcome-based accountability: The platform should not define success by the number of projects listed or roadshows held. It should track independent replication, pilot completion, first customers, two- or three-year survival, productivity or energy gains, and additional private capital attracted per unit of public expenditure.
Pilots should also contain sunset clauses and independent evaluation. In one WIPO GREEN project in Beijing, organizers identified 10 needs, sourced more than 38 technologies, and ultimately deployed two solutions (WIPO GREEN acceleration projects). A transparent funnel from listing to deployment provides far more policy value than a large headline number alone.
Conclusion: The Patent Office as an Interface, Not an Omnipotent Planner
Constructive reform does not require dismissing the achievements of the patent system or expecting patent examiners to become engineers, investors, and entrepreneurs at the same time. The most valuable institutional upgrade would be to develop the patent office from a rights-examination authority into a trusted and transparent interface within the national innovation network. On one side are inventors' rights and technical disclosures. On the other are enterprise demand, validation facilities, capital, industrial parks, and public procurement.
The principle is not to grant patents only to inventions that experts believe will be valuable. It is to ensure that every invention meeting the law receives equal access to protection, while technologies whose owners voluntarily seek validation and demonstrate genuine potential receive a faster opportunity to reach society. Statutory examination must remain neutral. Value assessment must remain optional. Expert judgment must be constrained. Public funding must follow milestones. Trade secrets must be respected, and commercialization outcomes must be evaluated over time.
When an innovation system begins to measure the problems solved, products created, and social value delivered, patent volume can become genuine national capability. The patent office cannot carry the entire innovation system, but it can become one of the most important places where invention stops being a document and starts becoming progress.